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ABSTRACT
Background    Ogi, one main component of boiogito 
(BOT), is reported to have an effect on hypercholester-
olemia and NAFLD. In this experiment, we examined 
effects of ogi on the progression of hypercholesterolemia 
and fatty liver induced by high-cholesterol diet in rats 
and compared with the effects of ogi combined with 
ginger or hesperidin. 
Methods    Hypercholesterolemia and fatty liver were 
induced by a high cholesterol diet in rats. Extract of ogi, 
ogi with hesperidin, and ogi with ginger were added to 
the high-cholesterol diet, respectively. Ezetimibe was 
also added to the high-cholesterol diet as a positive con-
trol. After 6 and 12 weeks, body, liver and adipose tissue 
weights, blood chemistry, lipid-related and inflammato-
ry-related factors were examined.
Result    The high cholesterol diet increased body, liver 
and adipose tissue weights, and serum cholesterol con-
centrations. Ogi, ogi with hesperidin or ginger and ezeti-
mibe improved them. In the histological examinations, 
we observed a significant improvement after treatment. 
The lipid-related factors (RBP4, HFABP and CFABP) 
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were improved by treatment. Biomarkers of cholesterol 
synthesis (lathosterol) and absorption (campesterol, beta-
sitosterol) were lower in the treatment groups. Inflamma-
tory-related factors (MCP1, CCR2 and TNF-alpha) and 
ICAM-1 were ameliorated after treatment, especially by 
ogi with ginger.
Conclusion    Ogi, ogi with hesperidin or ginger have a 
similar effect of BOT and ezetimibe on hypercholester-
olemia and fatty liver. Ogi with ginger reveals a stronger 
additive effect with no significant difference. However, 
as for the anti-inflammatory (MCP1, CCR2 and TNF-
alpha) and anti-arteriosclerotic (ICAM-1) effects, addi-
tive effects of ogi with ginger are more potent than that 
of ogi alone or ezetimibe.
Key words    fatty liver; ginger; hesperidin; hypercholes-
terolemia; ogi
The increased prevalence of hypercholesterolemia and 
fatty liver diseases has provided an increasingly negative 
connotation toward lipids and cardiovascular diseases 
(CVD), such as atherosclerosis and hypertension.1, 2 
Non-alcoholic fatty liver disease (NAFLD) occurs more 
frequently in patients with hypercholesterolemia.3 Dur-
ing the past few years, increasing evidence shows that 
NAFLD has also become a multisystem disease that 
affects many extra-hepatic organ systems, including 
the heart and the vascular system.4 Much experimental, 
clinical and epidemiological evidence supports a strong 
association between NAFLD and CVD, especially ath-
erosclerosis.5, 6
 A lot of lipid metabolism-related molecules and 
inflammatory cytokines are associated with the progres-
sion of hypercholesterolemia and NAFLD. Retinol bind-
ing protein 4(RBP4) is a 21 kDa secreted protein that is 
the transport protein for vitamin A (retinol) in blood.7 It 
takes part in the control of metabolic and proliferative 
cell functions,8 including steatogenesis.9 The RBP4 gene 
has been linked to increasing fasting glucose levels10 and 
related to hypercholesterolemia and NAFLD.11 Heart-
type fatty acid binding protein (HFABP) and cutaneous 
fatty acid-binding protein (CFABP) belong to the fatty 
acid binding protein (FABP) super-family, which is as-
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signed to transport fatty acids towards the mitochondria 
for beta-oxidation and energy expenditure.12, 13 Recent 
findings indicate that monocyte chemoattractant protein 
1 (MCP1) and its receptor C-C chemokine receptor type 
2 (CCR2) play a key role in hypercholesterolemia14 and 
CVD.15 Intercellular adhesion molecule-1 (ICAM-1) is 
over expressed in conditions with evidence of endothe-
lial inflammation such as atherosclerosis.16 TNF-alpha 
plays a similar role with ICAM-1 in atherosclerosis.17 
Therefore, in this study, we have monitored the expres-
sion of RBP4, HFABP, CFABP, MCP1, CCR2, ICAM-1 
and TNF-alpha to detect the mechanisms of hypercho-
lesterolemia and atherosclerosis.
 Based on evidence from our previous study, we 
proved that boiogito (BOT) has a protective effect on 
the progression of hypercholesterolemia and fatty liver. 
And the anti-inflammatory (MCP1, CCR2) and anti-
arteriosclerotic (ICAM-1) effects of BOT are more 
potent than ezetimibe.18 Our results are consistent with 
another previous study.19 Ogi (Astragalus membrana-
ceus Bunge), one main component of BOT, has been 
reported to have an effect on hypercholesterolemia and 
NAFLD. Ogi showed statistically significant beneficial 
effects on alanine aminotransferase (ALT) and glutam-
yltransferase activity,26 and significantly lowered plasma 
total cholesterol by 45.8%, triglycerides by 30%, and 
low-density lipoprotein-cholesterol (LDL-C) by 47.4%, 
comparable to simvastatin.27 We have also proven that 
ginger (Zingiber officinale Roscoe) and hesperidin could 
improve hypercholesterolemia and NAFLD by inhibit-
ing both the synthesis and absorption of cholesterol and 
regulating the expression of mRNA for RBP4, HFABP 
and CFABP.11, 20 We have also proven that hesperidin 
combined with ginger has a stronger effect than hes-
peridin alone on hypercholesterolemia.21 However, the 
inhibitory effect of the key components of BOT (ogi and 
ginger) on hypercholesterolemia and NAFLD has not yet 
been proven. Moreover, the synergistic action of ogi with 
hesperidin is unclear. In this experiment, we examined 
the effects of ogi on the progression of hypercholesterol-
emia and fatty liver induced by high-cholesterol diet in 
rats and compared with the effects of ogi combined with 
ginger or hesperidin. Furthermore, we have studied the 
mechanism of these kampo components on hypercholes-
terolemia and the protective effect on atherosclerosis.
MATERIALS AND METHODS
Rats and feeding method
Sixty 8-week-age male Wistar rats (purchased from Charles 
River Laboratories Japan) were acclimated in an air-condi-
tioned room at 25 °C with 55% humidity and given standard 
chow for 3 days. Then the rats were divided into six groups: 
control group (C, n = 10), high-cholesterol diet group (H, n = 
10), high-cholesterol diet with ogi group (HO, n = 10), high-
cholesterol diet with ogi and hesperidin group (HOH, n = 
10), high-cholesterol diet with ogi and ginger group (HOG, 
n = 10), high-cholesterol diet with ezetimibe group (HE, n 
= 10). The rats in each group were numbered from 1 to 10. 
Group C was fed a standard rat diet (moisture 8.83%, pro-
tein 25.13%, fat 4.92 %, fiber 4.42% and crude ash 6.86%, 
CE-2; Japan Clea, Tokyo, Japan). A high-cholesterol diet11, 
20 was supplied for Group H; it was made by adding 2% 
cholesterol and 0.5% cholic acid to the standard diet. The 
high-cholesterol diet with ogi was made by adding 1% ogi 
extract to the high-cholesterol diet. The high-cholesterol diet 
with ogi and hesperidin was made by adding 1% ogi extract 
and 0.08% hesperidin11 (Wako Pure Chemical Industries, 
Osaka, Japan). The high-cholesterol diet with ogi and ginger 
was made by adding 1% ogi extract and 1% ginger extract. 
Ogi and ginger extracts were purchased from Tsumura & 
CO. (Tokyo). The high-cholesterol diet with ezetimibe was 
made by adding 0.0006% of ezetimibe (LKT laboratories, 
St Paul, MN). The concentrations of the extracts adminis-
tered were calculated based on body surface area. Adult pa-
tients take ogi, ginger extract, hesperidin and ezetimibe 15 g, 
15 g, 1.2 g and 8 mg per day, respectively. The body surface 
area conversion coefficient from humans to rats is 0.018. 
The amount of feed for each rat was regulated to 25 g/day 
and water was supplied ad libitum. Body weights, systolic 
and diastolic blood pressure and heart rate were measured 
every week. Blood pressure and heart rate were measured 
by a noninvasive computerized tail-cuff method (BP-98A; 
Softron, Tokyo). 
Sample collection
On days 42 and 84, 5 rats of each group in the order of 
how they were numbered were sacrificed by collecting 
blood from the heart under pentobarbital anesthesia af-
ter fasting for 12 h. Liver tissue, adipose tissue around 
the left kidney, and abdominal aorta were removed for 
specimen, and then portions of the samples were stored 
in a 10% formalin solution for hematoxylin and eosin 
(HE) and oil red O staining.22 The remaining samples 
were immediately transferred into EP tubes containing 
500 μL of RNA later (Ambion, Austin, TX), quickly 
frozen in liquid nitrogen, and stored at –80 °C. Blood 
chemistry was analyzed for rats using an auto analyzer 
at an accredited clinical laboratory (SRL, Tokyo).
ICAM-1 and RBP4 enzyme-linked immunosorbent 
assay (ELISA)
Serum samples were applied for an ELISA of ICAM-1 
(R&D, Minneapolis, MN) and RBP4 (Aviscera Bioscience), 
according to the manufacturer’s instructions. 
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RT-PCR 
Total RNA from the liver and adipose tissue around 
the left kidney was extracted using TRIzol reagent ac-
cording to the manufacturer’s instructions (Promega, 
Carlsbad, CA). A semiquantitative real-time polymerase 
chain reaction (RT-PCR) was performed using Line-
Gene (Toyobo, Tokyo) and SYBR Green I (Roche, 
Basel, Switzerland). The detection was executed at the 
extension reaction stage in each cycle. The primer sets 
for RBP4, HFABP, CFABP, MCP1, CCR2 and beta-
actin mRNA were all synthesized by Hokkaido System 
Science (Sapporo, Japan). The sequence of each primer 
is listed in Table1. Using the 2−ΔCT method, mRNA ex-
pression was semi-quantitatively measured as a relative 
amount of each target RNA to a known housekeeping 
gene (beta-actin) expression level. 
Western blotting
Proteins from the liver were extracted using CelLytic 
MT according to the manufacturer’s instructions (Sigma, 
St. Louis, MO). We performed western blotting with 
20 mg/mL of proteins and the i-Blot gel transfer system 
(Invitrogen, Tokyo). Anti- TNF-alpha (1:500 dilutions, 
Sigma) and beta-actin (MBL, Nagoya, Japan) antibodies 
were used in the study according to the manufacturer’s 
instructions. Chemiluminescent signals were detected 
within 1 min with LAS-4000 (Fujifilm, Tokyo). The gels 
were run under the same experimental conditions. The 
expression of TNF-alpha was normalized by beta-actin. 
The Gel-Pro Analyzer 4.0 software (Media Cybernetics, 
Table 1. The sequence of each PCR primer
Gene Primer
RBP4 Forward 5´ -gacaaggctcgtttctctgg-3´
Reverse 5´ -gactcgtcccttggctgtag-3´
HFABP Forward 5´ -ctagcatgagggaagcaagg-3´
Reverse 5´ -tgcttcatccagacaagtgg-3´
CFABP Forward 5´ -gggctggctcttaggaagat-3´
Reverse 5´ -aaaacacggtcgtcttcacc-3´
MCP1 Forward 5´ -ctgtagcatccacgtgctgt-3´
Reverse 5´ -tgctgctggtgattctcttg-3´
CCR2 Forward 5´ -gatcctgcccctacttgtca-3´
Reverse 5´ -agatgagcctcacagcccta-3´
Beta-actin Forward 5´ -gtagccatccaggctgtgtt-3´
Reverse 5´ -ccctcagatgggcacagt-3´
CCR2, C-C chemokine receptor type 2; CFABP, cutaneous fatty 
acid-binding protein; HFABP, heart fatty acid-binding protein; 
MCP1, monocyte chemoattractant protein-1; PCR, polymerase 
chain reaction; RBP4, retinol-binding protein 4.
Rockville, MD) was used to analyze the integrating opti-
cal density of target band.
Immunohistochemical studies
During the immunohistochemical analyses, 4% parafor-
maldehyde-fixed aorta tissue specimens were processed. 
Anti-ICAM-1 (Abcam, Cambridge, United Kingdom) was 
used. As a negative control, tissues were stained without 
the primary antibody. The optical densities were measured 
by Image-Pro Plus v 6.0 software (Media Cybernetics, 
Rockville, MD).
The condition of LC/MS/MS analysis
Lathosterol, campesterol and beta-sitosterol were analyzed 
using a HPLC Prominence (Shimadzu, Kyoto, Japan) cou-
pled with a mass spectrometer (AB SCIEX QTRAP 5500 
LC/MS/MS System, SCIEX, Tokyo). In brief, separations 
of lathosterol, campesterol and beta-sitosterol were car-
ried out using a Poroshell 120 EC-C18 column 2.1 × 150 
mm, 2.7 μm particle size (Agilent Technologies, CA). The 
elution (150 µL/min) was completed at 40 °C in 25 min 
with linear gradient from 20% eluent B (ethanol) to 80% 
of eluent B (acetonitrile).The injection volume was 10 
µL. The LC–MS instrument was operated in the positive 
atmospheric pressure chemical ionization (APCI) mode 
with corona current of 3 μA, and capillary temperature 
of 500 °C. Declustering and entrance potential were set 
at 60 and 10 V, respectively. MS/MS spectra at m/z 315 
were obtained, and parameters for the specific MRM 
transition were optimized. The collision energy was 30 
V. MRM transition of 315.0 → 176.0 was found to be the 
optimal transitions.
Statistical analyses
The data are expressed as the means ± standard devia-
tion. Statistical comparisons were made using the two in-
dependent samples t-test by SPSS 11.0J (IBM, Armonk, 
NY). P < 0.05 was considered statistically significant.
RESULTS
Histological examination of liver tissues
From hematoxylin-eosin staining we can found that 
the fatty degeneration (steatosis) of liver was observed 
in high-cholesterol diet-fed Groups, but not in Group 
C. The tiny and large vacuoles as well as pleomorphic 
nuclei were more conspicuous in treatment groups than 
in Group H (Fig. 1A). Oil red O staining revealed the 
same changes that the livers in all high-cholesterol diet 
supplemented groups were filled with microvesicular or 
macrovesicular fat deposits; they were depicted as red-
dish deposits (Fig. 1B). Groups HOG and HE seems to 
show better effect (× 400).
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Fig. 1. Histopathological examination of liver. 
A: Fatty degeneration (steatosis) of the liver is observed in the high-cholesterol diet–fed groups (H, HO, HOH, HOG and HE), but not in 
Group C in hematoxylin-eosin stained tissues. Fatty changes increased with time to a greater extent in Group H than Groups HO, HOH, 
HOG and HE. B: Oil red O staining revealed more lipid droplets (stained red) to be accumulated in vacuoles in Group H than other 
groups. 6W: 6 weeks, 12W: 12 weeks. C: control, standard diet for 6 and 12 weeks (n = 5); H: high-cholesterol diet for 6 and 12 weeks (n = 
5); HO: high-cholesterol diet with ogi for 6 and 12 weeks (n = 5); HOH: high-cholesterol diet with ogi and hesperidin for 6 and 12 weeks 
(n = 5); HOG: high-cholesterol diet with ogi and ginger for 6 and 12 weeks (n = 5); HE: high-cholesterol diet with ezetimibe for 6 and 12 
weeks (n = 5). Bars express 25 μm.
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Fig. 2.  
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Fig. 2. Histopathological examination of adipose tissue. 
The larger fat cells were observed in high-cholesterol diet-fed groups (H, HO, HOH, HOG and HE), but not in Group C (55.16 ± 7.21 μm 
and 55.78 ± 6.58 μm after 6 and 12 weeks respectively) in hematoxylin-eosin stained tissues. Fat cells enlarged with time to a greater ex-
tent in Group H (90.91 ± 12.73 and 94.03 ± 8.54 μm in diameter after 6 and 12 weeks respectively) than Groups HO, HOH, HOG and HE 
(54.94 ± 9.22 μm and 59.16 ± 8.93 μm, 53.28 ± 8.40 μm and 56.88 ± 7.99 μm, 46.09 ± 7.66 μm and 54.54 ± 8.91 μm, 58.91 ± 8.25 μm and 
59.06 ± 7.00 μm in diameter after 6 and 12 weeks respectively). 6W: 6 weeks, 12W: 12 weeks. C: control, standard diet for 6 and 12 weeks 
(n = 5); H: high-cholesterol diet for 6 and 12 weeks (n = 5); HO: high-cholesterol diet with ogi for 6 and 12 weeks (n = 5); HOH: high-
cholesterol diet with ogi and hesperidin for 6 and 12 weeks (n = 5); HOG: high-cholesterol diet with ogi and ginger for 6 and 12 weeks (n 
= 5); HE: high-cholesterol diet with ezetimibe for 6 and 12 weeks (n = 5). Bars express 50 μm.
Histological examination of adipose tissue 
The larger fat cells were observed in high-cholesterol 
diet-fed groups (H, HO, HOH, HOG and HE), but not in 
Group C. It was more notable in Group H than Groups 
HO, HOH, HOG and HE (Fig. 2, × 400).
Body, liver, and adipose tissue weights
During the whole experiment, the amount of feed for 
each rat was regulated to 25g/day and there was no 
significant difference in each group. As Table 2 shows, 
there were no significant differences in the baseline of 
body weights at the beginning of the experiment. High-
cholesterol diet increased body, liver and adipose tissue 
weights in Group H compared with Group C both after 
6 and 12 weeks (P < 0.05). Body, liver and adipose tis-
sue weights were significantly lower in Groups HO, 
HOH, HOG, HE than Group H after 6 and 12 weeks (P 
< 0.05). Liver weights in Group HE were lower than that 
in Groups HO, HOH and HOG after 6 weeks (P < 0.05).
Blood chemistry and cholesterol concentrations
As Table 3 shows, the high-cholesterol diet increase the 
concentrations of LDL-C, TC, ALT, ALP, LDH and 
reduce the concentrations of HDL-C in Group H com-
pared with Group C after 6 and 12 weeks in serum (P 
< 0.05). Compared with Group H, the concentrations of 
LDL-C and TC decreased in Groups HOH, HOG, HE 
after 6 weeks and Groups HO, HOH, HOG, HE after 12 
weeks (P < 0.05), while the concentration of HDL-C has 
a opposite trends (P < 0.05). After 12 weeks, the activi-
ties of ALT, ALP, LDH reduced in different degree in 
Groups HO, HOH, HOG, HE compared with Group H 
(P < 0.05). The BS, TBil, TG and Cr have no significant 
differences during the experiment.
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Lathosterol, Campesterol and beta-Sitosterol con-
centrations determined by LC/MS/MS
Concentrations of serum lathosterol decreased in the 
Group HO, HOH, HOG and HE compared with Group 
H (Table 4, P < 0.05). The same trend was found in the 
concentrations of serum campesterol and beta-sitosterol, 
Table 2. Body, liver and Lipid weights
C H HO HOH HOG HE
Body
weights (g)
0W 308.68 ± 6.72 315.86 ± 8.56 310.47 ± 9.23 310.67 ± 8.77 311.73 ± 7.96 311.57 ± 7.59
6W 453.03 ± 16.69 503.12 ± 17.27* 456.91 ± 17.68† 456.20 ± 22.70† 453.88 ± 20.55† 451.48 ± 18.23†
12W 507.97 ± 24.12 576.09 ± 20.54* 497.23 ± 20.29† 503.52 ± 29.72† 506.20 ± 15.24† 510.63 ± 8.27†
Liver
weights (g)
6W   11.66 ± 1.09   19.62 ± 1.90*   16.39 ± 1.03†   17.21 ± 1.09†   16.79 ± 2.15†   13.24 ± 1.76†‡§||
12W   13.26 ± 1.48   28.99 ± 4.42*   19.90 ± 5.03†   20.44 ± 3.06†   20.22 ± 3.32†   16.79 ± 3.40†
Adipose tissue
weights (g)
6W     2.59 ± 0.67     3.74 ± 0.40*     2.35 ± 0.70†      2.78 ± 0.89†      2.09 ± 0.69†     2.58 ± 0.48†
12W     3.53 ± 0.55     5.88 ± 0.50*     2.09 ± 0.50†      2.99 ± 0.74†      3.35 ± 0.30†     2.20 ± 0.90†||
C: control, standard diet for 6 and 12 weeks (n = 5); H: high-cholesterol diet for 6 and 12 weeks (n = 5); HO: high-cholesterol diet with ogi 
for 6 and 12 weeks (n = 5); HOH: high-cholesterol diet with ogi and hesperidin for 6 and 12 weeks (n = 5); HOG: high-cholesterol diet 
with ogi and ginger for 6 and 12 weeks (n = 5); HE: high-cholesterol diet with ezetimibe for 6 and 12 weeks (n = 5). *P < 0.05 vs. Group C, 
†P < 0.05 vs. Group H, ‡P < 0.05 vs. Group HO, §P < 0.05 vs. Group HOH, ||P < 0.05 vs. Group HOG. Data are expressed as the means ± 
standard deviation. 0W: 0 week, 6W: 6 weeks, 12W: 12 weeks.
Table 3. Blood chemistry and cholesterol concentrations
C H HO HOH HOG HE
LDL-C (mg/dL) 6W 9.20 ± 3.19 53.00 ± 17.90* 54.75 ± 18.91 35.75 ± 6.24†‡ 28.33 ± 3.06†‡ 9.00 ± 1.22†‡§||
12W 9.20 ± 1.30 65.67 ± 15.95* 29.60 ± 10.11† 41.00 ± 9.49†‡ 31.75 ± 9.84† 28.20 ± 2.17†§
HDL-C (mg/dL) 6W 17.20 ± 4.02 6.40 ± 1.67* 6.60 ± 1.14 12.00 ± 2.74†‡ 13.80 ± 4.15†‡ 16.80 ± 2.28†‡§
12W 19.00 ± 2.35 13.00 ± 1.63* 17.25 ± 0.96† 18.00 ± 1.00† 16.00 ± 1.00† 17.75 ± 2.06†
TC (mg/dL) 6W 56.80 ± 15.01 150.25 ± 34.06* 124.00 ± 33.09 106.00 ± 20.83† 90.00 ± 13.53†‡ 54.60 ± 7.16†‡§||
12W 55.60 ± 8.20 160.75 ± 48.75* 83.80 ± 13.05† 115.60 ± 23.54† 120.00 ± 40.28† 94.00 ± 9.43†
TG (mg/dL) 6W 20.75 ± 5.50 18.60 ± 8.11 19.75 ± 4.57 21.20 ± 4.92 15.25 ± 3.40 13.00 ± 5.57
12W 26.80 ± 8.81 31.80 ± 2.59 23.00 ± 6.96 28.50 ± 8.76 39.00 ± 10.10 17.40 ± 11.59
ALT (U/L) 6W 30.00 ± 3.67 50.80 ± 11.30* 70.00 ± 2.00 52.00 ± 3.39‡ 46.33 ± 9.29‡ 91.33 ± 20.53†‡§||
12W 30.40 ± 4.16 168.00 ± 53.84* 35.67 ± 3.79† 70.60 ± 19.19† 55.00 ± 14.14† 36.50 ± 10.47†
ALP (U/L) 6W 192.00 ± 25.50 372.75 ± 32.47* 363.67 ± 8.14 327.00 ± 29.46† 314.33 ± 28.94†‡ 390.33 ± 20.74§||
12W 202.00 ± 25.29 515.67 ± 36.09* 258.80 ± 29.18† 289.33 ± 27.75† 264.33 ± 38.89† 265.25 ± 39.66†
TBil (mg/dL) 6W 0.05 ± 0.01 0.03 ± 0.01 0.041 ± 0.02 0.04 ± 0.01 0.03 ± 0.02 0.06 ± 0.00
12W 0.06 ± 0.01 0.04 ± 0.01 0.05 ± 0.02 0.05 ± 0.01 0.06 ± 0.02 0.05 ± 0.01
Cr (mg/dL) 6W 0.34 ± 0.06 0.31 ± 0.03 0.42 ± 0.10 0.32 ± 0.05 0.41 ± 0.02 0.36 ± 0.04
12W 0.37 ± 0.05 0.41 ± 0.09 0.40 ± 0.10 0.33 ± 0.03 0.32 ± 0.07 0.35 ± 0.07
LDH (U/L) 6W 156.00 ± 18.46 516.67 ± 32.75* 262.00 ± 32.08† 277.33 ± 25.48† 356.33 ± 33.56†‡§342.67 ± 35.84†‡§
12W 177.50 ± 64.57 599.00 ± 19.80* 192.00 ± 48.08† 214.00 ± 16.46† 318.00 ± 87.68† 282.33 ± 82.71†
BS (mg/dL) 6W 103.40 ± 7.54 92.80 ± 6.14 89.60 ± 10.41 108.33 ± 4.51 104.80 ± 7.56 93.67 ± 6.11
12W 95.80 ± 10.66 101.80 ± 6.14 78.00 ± 15.07 82.20 ± 13.74 75.00 ± 13.17 103.20 ± 18.90
C: control, standard diet for 6 and 12 weeks (n = 5); H: high-cholesterol diet for 6 and 12 weeks (n = 5); HO: high-cholesterol diet with ogi 
for 6 and 12 weeks (n = 5); HOH: high-cholesterol diet with ogi and hesperidin for 6 and 12 weeks (n = 5); HOG: high-cholesterol diet 
with ogi and ginger for 6 and 12 weeks (n = 5); HE: high-cholesterol diet with ezetimibe for 6 and 12 weeks (n = 5). *P < 0.05 vs. Group C, 
†P < 0.05 vs. Group H, ‡P < 0.05 vs. Group HO, §P < 0.05 vs. Group HOH, ||P < 0.05 vs. Group HOG. Data are expressed as the means ± 
standard deviation. 6W: 6 weeks, 12W: 12 weeks.
ALP, alkaline phosphatase; ALT, alanine aminotransferase; BS, blood sugar; Cr, creatinine; HDL-C, high-density lipoprotein cholesterol; 
LDH, lactate dehydrogenase; LDL-C, low-density lipoprotein cholesterol; TBil, total bilirubin; TC, total cholesterol; TG, triglyceride.
which were lower in the treatment groups (HO, HOH, 
HOG and HE) than Group H (P < 0.05).
ICAM-1 and RBP4 in serum
ICAM-1 concentrations were increased in Group H com-
pared with Groups C, HO, HOH, HOG and HE group 
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Table 4. Lathosterol, campesterol, and beta-sitosterol concentrations in serum determined by LC/MS/MS
C H HO HOH HOG HE
Lathosterol (10-2 μg/mL) 1.81 ± 0.29 3.84 ± 0.43* 2.53 ± 0.88† 2.55 ± 0.37† 2.40 ± 0.41† 2.09 ± 0.79†
Campesterol (μg/mL) 1.19 ± 0.46 2.26 ± 0.18* 1.36 ± 0.36† 1.50 ± 0.33† 1.40 ± 0.84† 1.29 ± 0.04†
beta-Sitosterol (μg/mL) 0.77 ± 0.27 2.51 ± 0.35* 1.46 ± 0.39† 1.47 ± 0.11† 0.92 ± 0.24†‡§ 0.95 ± 0.51†‡§
C: control, standard diet for 6 and 12 weeks (n = 5); H: high-cholesterol diet for 12 weeks (n = 5); HO: high-cholesterol diet with ogi for 12 
weeks (n = 5); HOH: high-cholesterol diet with ogi and hesperidin for 12 weeks (n = 5); HOG: high-cholesterol diet with ogi and ginger 
for 12 weeks (n = 5); HE: high-cholesterol diet with ezetimibe for 12 weeks (n = 5). *P < 0.05 vs. Group C, †P < 0.05 vs. Group H, ‡P < 0.05 
vs. Group HO, §P < 0.05 vs. Group HOH, ||P < 0.05 vs. Group HOG. Data are expressed as the means ± standard deviation.
after 12 weeks (Fig. 3, P < 0.05). Compared with other 
treatment groups, Group HOG seemed to have the best 
effect. RBP4 concentrations were increased in Group 
H compared with the other groups, including Groups 
HOG and HE after 6 weeks (P < 0.05) and Groups HO, 
HOH, HOG and HE after 12 weeks (P < 0.05). It has 
less concentration in Group HOG than Group HO after 
12 weeks (P < 0.05).
mRNA expression in liver and adipose tissue
As Fig. 4 shows, RBP4 mRNA expression in liver in 
Group H was significantly increased compared to that 
in other groups (P < 0.05). HFABP mRNA expression 
in Group H was significantly increased compared to 
that in Groups C, HOH, HOG and HE after 6 weeks (P 
< 0.05), and then continued to increase after 12 weeks 
compared to all the other 5 groups (P < 0.05). Compared 
with the other groups, the mRNA expression of CFABP 
in liver in Group H were higher than that in the other 
groups after 12 weeks (P < 0.05), whereas they were not 
obvious after 6 weeks. Compared with the other groups, 
the mRNA expression of MCP1 in liver in Group H 
remained high during the entire experiment, especially 
after 12 weeks. And Group HOG revealed a better effect 
than Groups HO and HE at 12 weeks (P < 0.05). The ex-
pressions of CCR2 in Groups HO, HOH and HOG were 
lower than that in Group H (P < 0.05) after 6 and 12 
weeks, but in Group HE it was not significantly reduced 
than that in Group H after 6 and 12 weeks.
 The same trend was found in adipose tissue around 
Fig. 3.  
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Fig. 3. ICAM-1 and RBP4 concentrations in serum. 
ICAM-1 and RBP4 concentrations in standard diet group (C, n = 5), high-cholesterol diet group (H, n = 5), high-cholesterol diet with ogi 
group (HO, n = 5), high-cholesterol diet with ogi and hesperidin group (HOH, n = 5), high-cholesterol diet with ogi and ginger group (HOG, 
n = 5) and high-cholesterol diet with ezetimibe group (HE, n = 5). Dotted and shaded columns represent 6 and 12 weeks, respectively. *P 
< 0.05 vs. Group C, †P < 0.05 vs. Group H, ‡P < 0.05 vs. Group HO. 6W: 6 weeks, 12W: 12 weeks.
ICAM-1, intercellular adhesion molecule-1; RBP4, retinol-binding protein 4.
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Fig. 4. Changes of mRNA expression with time in liver and adipose tissue. 
Levels of RBP4, HFABP, CFABP, MCP1 and CCR2 against beta-actin mRNA expression are shown as above histogram. The left-side 
graphs show the expression in liver. The right-side graphs show the expression in adipose tissue around the left kidney. C: control, stan-
dard diet for 6 and 12 weeks (n = 5); H: high-cholesterol diet for 6 and 12 weeks (n = 5); HO: high-cholesterol diet with ogi for 6 and 12 
weeks (n = 5); HOH: high-cholesterol diet with ogi and hesperidin for 6 and 12 weeks (n = 5); HOG: high-cholesterol diet with ogi and 
ginger for 6 and 12 weeks (n = 5); HE: high-cholesterol diet with ezetimibe for 6 and 12 weeks (n = 5). Dotted and shaded columns repre-
sent 6 and 12 weeks, respectively. *P < 0.05 vs. Group C, †P < 0.05 vs. Group H, ‡P < 0.05 vs. Group HO, §P < 0.05 vs. Group HOH, ¶P 
< 0.05 vs. Group HE. 6W: 6 weeks, 12W: 12 weeks.
CCR2, C-C chemokine receptor type 2; CFABP, cutaneous fatty acid-binding protein; HFABP, heart fatty acid-binding protein; MCP1, 
monocyte chemoattractant protein-1; RBP4, retinol-binding protein 4.
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the left kidney. The up-regulation of RBP4, HFABP 
and CFABP mRNA expression were found in Group 
H. After treatment, they were decreased. MCP1 and 
CCR2 mRNA expression was not observed differences 
between Group H and Group HE. However Group HOG 
showed significant differences compared with other 
treatment groups (P < 0.05).
ICAM-1immunostaining expression in aorta 
As shown in Fig. 5A, after 12 weeks, seldom ICAM-
1immunostaining (Red-brown deposits indicate positive 
staining) was found on the whole layers of thoracic aor-
tas in Group C. Significantly positive ICAM-1 immunos-
taining was observed in Group H and mainly localized 
on the endothelial layers. Positive ICAM-1 immunos-
taining was also observed in Groups HO, HOH, HOG 
and HE, but less than Group H (× 400). Mean optical 
density values of ICAM-1 are showed in Fig. 5B. The 
photographs generated were quantitatively analyzed the 
optical density of ICAM-1 by Image - Pro Plus. After 
treatment, the expressions in Groups HO, HOH, HOG 
and HE were decreased than Group H. And Group HOG 
Fig. 5. ICAM-1 expression in aorta after 12 weeks.
A: Immunohistochemistry analyses of ICAM-1 in aorta (The arrows indicate positive expressions). B: Mean optical density values of 
ICAM-1. The optical density of ICAM-1 were quantitatively analyzed with Image - Pro Plus after 12 weeks. C: control, standard diet for 
12 weeks (n = 5); H: high-cholesterol diet for 12 weeks (n = 5); HO: high-cholesterol diet with ogi for 12 weeks (n = 5); HOH: high-cho-
lesterol diet with ogi and hesperidin for 12 weeks (n = 5); HOG: high-cholesterol diet with ogi and ginger for 12 weeks (n = 5); HE: high-
cholesterol diet with ezetimibe for 12 weeks (n = 5). *P < 0.05 vs. Group C, †P < 0.05 vs. Group H, ‡P < 0.05 vs. Group HO, ¶P < 0.05 vs. 
Group HE.  Bars express 25 μm.
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was significantly lower compared with Groups HO and 
HE (P < 0.05).
TNF-alpha western blotting expression in liver
After 12weeks, the TNF-alpha protein levels in liver 
of Groups HO, HOH, HOG and HE were significantly 
inhibited compared with that of Group H (Fig. 6A, P 
< 0.05). It has less expression of TNF-alpha protein in 
Group HOG than Group HO and HE (Fig. 6B, P < 0.05).
Blood pressure and heart rate
No significant changes in systolic or diastolic blood 
pressure and heart rates were observed during the ex-
periment (data not shown).
ated the serum lipid and lipoprotein levels as well as 
the steatotic process by biochemical and histological 
methods, respectively.23 The results showed that fatty 
liver was well developed with long-term high choles-
terol diets, and hepatocytes were filled with many lipid 
droplets. This process was more evident in the portal 
zones, where fat hepatocytes were more numerous. It 
has reported that the abnormal serum levels of HDL-
C and LDL-C are associated with NAFLD and CVD.24 
Statins, hydroxyl-methylglutaryl-coenzyme A (HMG-
CoA) reductase inhibitors, are one kind of lipid-lowering 
drugs, which can inhibit cholesterol synthesis. They can 
well decrease LDL-C and increase HDL-C. However, 
they sometimes caused rhabdomyolysis and hepatitis. 
Kampo medicines are considered as a safe way to har-
monize the abnormal serum levels of HDL-C and LDL-
C and to minimize the side effects. We have already 
proved that BOT can improve blood chemistry and cho-
lesterol concentrations.18 In this experiment, we found 
that ogi, ogi with hesperidin, ogi with ginger and ezeti-
mibe could decrease the concentrations of LDL-C and 
TC and increase HDL-C. ALT and ALP activities (after 
6 weeks) in Group HE were significantly elevated than 
kampo groups. The reason may be kampo medicines 
have fewer side effects than ezetimibe. The marked 
elevation of ALT and ALP activities in Group H were 
consistent with our previous study.18 However, the ALT 
and ALP activities in Group HE were decreased after 12 
weeks, which was probably due to the individual differ-
ences in the rats.
 Lipid-soluble molecules share several aspects of 
physiology due to common adaptations that allow them 
to function in a hydrophilic environment. RBP4, the 
transport protein for vitamin A (retinol) in blood, plays 
the role during hypercholesterolemia through binding to 
specific nuclear receptors like the peroxisome prolifera-
tor-activated receptor (PPAR) and the retinoid X receptor 
(RXR).25 PPAR could directly regulate RBP4 expres-
sion, at least in certain tissues.26 On the other hand, the 
increase of RBP4 levels may potentially enhance retinoid 
availability for RXR-PPAR action, by promoting retinol 
transport to the periphery of the body.27 RBP4 has also 
been identified as an adipokine, which is involved in 
the modulation of glucose metabolism.28 Graham et al29 
reported that increased levels of RBP4 were associated 
with obesity and hypercholesterolemia. Thus, the mea-
surement of serum or plasma RBP4 levels is a helpful 
way for revealing metabolic disorders. In our experi-
ment, we also found the increased trend of RBP4 in 
serum as well as mRNA expression of liver and adipose 
with high cholesterol diet rats. Ogi, ogi with hesperidin, 
ogi with ginger and ezetimibe could decrease the expres-
Fig. 6. TNF-alpha expression in liver. 
A: Western blot analysis of TNF-alpha expression in liver. B: The 
TNF-alpha expression levels were quantitatively analyzed with 
Gel-Pro Analyzer 4. C: control, standard diet for 12 weeks (n = 5); 
H: high-cholesterol diet for 12 weeks (n = 5); HO: high-cholesterol 
diet with ogi for 12 weeks (n = 5); HOH: high-cholesterol diet with 
ogi and hesperidin for 12 weeks (n = 5); HOG: high-cholesterol 
diet with ogi and ginger for 12 weeks (n = 5); HE: high-cholesterol 
diet with ezetimibe for 12 weeks (n = 5). *P < 0.05 vs. Group C, 
†P < 0.05 vs. Group H, ‡P < 0.05 vs. Group HO, ¶P < 0.05 vs. 
Group HE. 
Fig. 6.  
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DISCUSSION
A high cholesterol diet can lead to high lipid levels and 
establish fatty liver model in rats. Del Moral ML et al 
administered a high cholesterol diet in rats, and evalu-
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sions of the up-regulated RBP4, suggesting their specific 
effects in alleviating hypercholesterolemia to be partly 
induced through a lowering of the RBP4 expressions.
 HFABP is a 15 kDa small protein consisting of 132 
amino acids.33 It is rich in the myocardium34 and pro-
duced by skeletal muscle,35 cardiomyocytes, kidney dis-
tal tubular cells,36 and specific parts of the brain.37 And 
CFABP is abundant in the psoriatic skin.38 HFABP and 
CFABP are thought to play key roles in fatty acid me-
tabolism, like fatty acid storage and transport.38 FABPs 
are also expressed in mononuclear cells (predominantly 
monocytes and macrophages).30 FABPs mRNA ex-
pressions have been reported to increase in abdominal 
white adipose tissue in rats fed a high cholesterol diet 
for 30 days.39 They were reported to be up-regulated in 
liver and adipose tissue of rats fed high-cholesterol diet 
for 12 weeks. Our previous study proved that HFABP 
and CFABP maintained high expression levels for 12 
weeks.11, 18 Here, this phenomenon was also demonstrat-
ed. HFABP and CFABP mRNA expressions in the liver 
and adipose tissue of high-cholesterol diet group were 
increased compared to Group C while decreased after 
treatment.
 Intestinal cholesterol absorption is a kind of active 
and selective process, which mediated by several trans-
porter proteins located at the intestinal brush border 
membrane. Cholesterol and plant sterols are taken up 
by the enterocyte through the Niemann-Pick C1 Like 1 
transporter.40 Moreover, the ATP-binding cassette (ABC) 
transporters G5 and G8 actively induced plant sterols ef-
flux and, to lesser extent cholesterol, back into the intes-
tinal lumen. In addition, ABCG5 and ABCG8 are locat-
ed at the canalicular membranes of hepatocytes, where 
they facilitate efflux of cholesterol and plant sterols into 
bile.41 Animal cell membranes normally contain only a 
single major class of sterol, cholesterol.42 However, plant 
cell membranes typically contain a complex mixture 
of sterols, such as lathosterol, campesterol and beta-
sitosterol,42, 43 which have similar structure with choles-
terol. The serum lathosterol concentration is an indicator 
of whole-body cholesterol synthesis and can reveal the 
expression of cholesterol synthesis.44 However, campes-
terol and beta-sitosterol are known to reduce blood cho-
lesterol levels, and indicated cholesterol absorption.45–47 
It is reported that high cholesterol absorption and low 
cholesterol synthesis are associated with increased se-
verity of coronary artery disease.48 However, in an ex-
periment, which takes plasma non-cholesterol sterols as 
a diagnostic tool, Noto et al also found increases in both 
cholesterol synthesis and absorption in pediatric hyper-
cholesterolemia as we found in the high-cholesterol diet 
group.49 In this experiment, concentrations of these three 
biomarkers were increased in Group H, while decreased 
after treatment, consistent with our previous research, in 
which concentrations of lathosterol, campesterol and be-
ta-sitosterol were simultaneously increased in high cho-
lesterol diet rats.11 Brahma Naidu P et al also proved that 
synthesis of cholesterol was increased in high fat diet 
rats, which was probably due to the increase HMG CoA 
reductase in liver.50 So, we have demonstrated that ogi, 
ogi with hesperidin, and ogi with ginger have a similar 
effect with BOT and ezetimibe on hypercholesterolemia 
and fatty liver. These kampo components can efficiently 
reduce cholesterol concentrations by inhibiting both ab-
sorption and synthesis by adjusting mRNA or enzymes 
associated with cholesterol absorption or synthesis.
 A lot of evidences showed that inflammatory fac-
tors could take part in the occurrence and development 
of hypercholesterolemia, NAFLD and atherosclerosis.6 
MCP1 and its receptor CCR2 are two valuable inflam-
mation related cytokines associated with NAFLD and 
atherosclerosis.51 They can be engendered by vascu-
lar endothelial cells, monocytes and vascular smooth 
muscle cells.52 It was reported that they would increase 
by hypercholesterolemia and obesity.53, 54 TNF-alpha, 
participated in many inflammatory diseases, was also 
up-regulated on atherosclerosis.55 In our experiment, 
kampo treatment groups could down-regulate the MCP1 
and CCR2 mRNA expression in both liver and adipose 
tissue. Ezetimibe showed a reduced trend however 
not significantly different. Ogi showed a stronger anti-
inflammatory effect when combined with ginger than 
other treatment groups. A similar effect was revealed 
on the protein expression of TNF-alpha in liver. Group 
HOG had advantage on anti-inflammatory effect during 
the whole experiment. 
 ICAM-1, one of the markers of endothelial cell 
activation, is expressed in endothelial cells, which has 
participated in neutrophil as well as monocyte migra-
tion, migration and adhesion of endothelial cells.56 Some 
studies proved that the concentration of serum ICAM-1 
correlated with the expression of ICAM-1 in the media 
and the vasa vasorum.57 Therefore, it is a reliable mea-
sure using the concentration of serum ICAM-1 to detect 
the expression of the molecule in the tissue of the aortic 
wall. It was reported that ICAM-1 was up-regulated 
after vascular injury in neointimal and medial smooth 
muscle cells.58 And experiment evidences also showed 
that the expressions of both serum ICAM-1 and tissue 
ICAM-1 were increased in the early stages of atheroscle-
rosis rats.57 In our experiment, both the concentration 
of serum ICAM-1 and expression of ICAM-1 in aorta 
were increased in Group H. Kampo components and 
ezetimibe could down-regulate the high expression with 
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high-cholesterol diet. Ogi combined with ginger still 
showed advantage both in serum and aorta. We specu-
late that down-regulated ICAM-1 may be one of the 
mechanisms to prevent atherosclerosis of ogi, ogi with 
hesperidin and ezetimibe, especially ogi combined with 
ginger.
 Our previous study proved that BOT has a protective 
effect on the progression of hypercholesterolemia and 
fatty liver induced by high-cholesterol diet in rats. BOT 
is composed of ogi (Astragalus membranaceus Bunge), 
boi (Sinomenium acutum Rehder et Wilson), sojyutsu 
(Atractylodes lancea De Candolle), ginger (Zingiber of-
ficinale Roscoe), taiso (Zizyphus jujuba Miller var. iner-
mis Rehder) and kanzo (Glycyrrhiza uralensis Fischer). 
Ogi and ginger are the key components of BOT. Wang 
D et al. reported that ogi could significantly decrease 
concentrations of TC and LDL-C and improved the ath-
erosclerosis profile.59 Matsuda A et al. also found that 
ginger tended to reduce RBP4 mRNA expression levels 
in the liver and visceral fat in hyperlipidemia.20 Wang 
X et al. revealed that hesperidin could improve hyper-
cholesterolemia and fatty liver by inhibiting both the 
synthesis and absorption of cholesterol.11 However few 
studies have assessed the mechanism of ogi on hyper-
cholesterolemia atherosclerosis as well as the synergistic 
action between ogi and hesperidin or ginger.
 In the present findings, three kampo component 
groups showed a similar effect with BOT and ezetimibe 
on hypercholesterolemia and fatty liver. These kampo 
components could efficiently reduce cholesterol concen-
trations by inhibiting both absorption and synthesis. The 
synergistic action of ogi with ginger showed stronger ef-
fect but had no significant difference. On the other hand, 
ogi combined with ginger revealed the most powerful 
anti-arteriosclerotic effect than other kampo components 
groups as well as ezetimibe group. According to ogi and 
ginger are the key components of BOT and the results 
above, we speculate that ogi has the similar effects with 
BOT both on the progression of hypercholesterolemia 
and arteriosclerosis, while ginger maybe helpful for oth-
er components of BOT especially on anti-inflammation 
and anti-arteriosclerosis.
Acknowledgments: We would like to express our sincere ap-
preciation for the fellowship and research grant from the Japan 
Research Foundation of Clinical Pharmacology (JRFCP). And 
we thank for Dr. K. Nagata’s assistance for LC/MS/MS studies.
The authors declare no conflict of interest. 
REFERENCES
  1 Mohamed AR, El-Hadidy WF, Mannaa HF. Assessment of 
the prophylactic role of aspirin and/or clopidogrel on experi-
mentally induced acute myocardial infarction in hypercho-
lesterolemic rats. DrugsRD. 2014;14:233-9. PMID: 25231707; 
PMCID: PMC4269823.
  2 Noland RC. Exercise and Regulation of Lipid Metabolism. 
Prog Mol Biol Transl Sci.2015;135:39-74. PMID: 26477910.
  3 Marchesini G, Moscatiello S, Di Domizio S, Forlani G. 
Obesity-associated liver disease. J Clin Endocrinol 
Metab.2008;93(11Suppl 1):S74-80. PMID: 18987273.
  4 Dick TJ, Lesser IA, Leipsic JA, Mancini GB, Lear SA. The 
effect of obesity on the association between liver fat and ca-
rotid atherosclerosis in a multi-ethnic cohort. Atherosclerosis. 
2013;226:208-13. PMID: 23141586.
  5 Sung KC, Wild SH, Kwag HJ, Byrne CD. Fatty liver, 
insulin resistance, and features of metabolic syndrome: re-
lationships with coronary artery calcium in 10,153 people. 
Diabetes care. 2012;35:2359-64. PMID: 22829522; PMCID: 
PMC3476919.
  6 Kim EJ, Kim BH, Seo HS, Lee YJ, Kim HH, Son HH, et al. 
Cholesterol-induced non-alcoholic fatty liver disease and ath-
erosclerosis aggravated by systemic inflammation. PloS one. 
2014;9:e97841. PMID: 24901254; PMCID: PMC4046981.
  7 Blaner WS. Retinol-binding protein: the serum transport 
protein for vitamin A. Endocr Rev. 1989;10:308-16. PMID: 
2550213.
  8 Desvergne B. RXR: from partnership to leadership in 
metabolic regulations. Vitam Horm. 2007;75:1-32. PMID: 
17368310.
  9 Larter CZ, Farrell GC. Insulin resistance, adiponectin, cyto-
kines in NASH: Which is the best target to treat? J Hepatol. 
2006;44:253-61. PMID: 16364488.
10 Meigs JB, Panhuysen CI, Myers RH, Wilson PW, Cupples LA.
 A genome-wide scan for loci linked to plasma levels of glu-
cose and HbA(1c) in a community-based sample of Cauca-
sian pedigrees: The Framingham Offspring Study. Diabetes. 
2002;51:833-40. PMID: 11872688.
11 Wang X, Hasegawa J, Kitamura Y, Wang Z, Matsuda A, 
Shinoda W, et al. Effects of hesperidin on the progression of 
hypercholesterolemia and fatty liver induced by high-cho-
lesterol diet in rats.J Pharmacol Sci. 2011;117:129-38. PMID: 
21979313.
12 Alhadi HA, Fox KA. Do we need additional markers of myo-
cyte necrosis: the potential value of heart fatty-acid-binding 
protein. QJM. 2004;97:187-98. PMID: 15028848.
13 Smathers RL, Petersen DR. The human fatty acid-binding 
protein family: evolutionary divergences and functions. 
Hum Genomics. 2011;5:170-91. PMID: 21504868; PMCID: 
PMC3500171.
14 Tous M, FerréN, Rull A, Marsillach J, Coll B, Alonso-Villaverde C,
 et al. Dietary cholesterol and differential monocyte che-
moattractant protein-1 gene expression in aorta and liver 
of apo E-deficient mice. Biochem Biophys Res Commun. 
2006;340:1078-84. PMID: 16403442.
15 Arakelyan A, Zakharyan R, Hambardzumyan M, Petrkova J, 
Olsson MC, Petrek M, et al. Functional genetic polymor-
phisms of monocyte chemoattractant protein 1 and C-C 
chemokine receptor type 2 in ischemic stroke. J Interferon 
Cytokine Res. 2014;34:100-5. PMID: 24083412.
16 Caravedo MA, Herrera PM, Mongilardi N, de Ferrari A, 
Davila-Roman VG, Gilman RH, et al. Chronic exposure to 
biomass fuel smoke and markers of endothelial inflammation. 
Indoor Air. 2015. PMID: 26476302.
17 Delgado-Roche L, Brito V, Acosta E, Pérez A, Fernández JR, 
Hernández-Matos Y, et al. Arresting progressive atherosclero-
79
Kampo components ameliorates dyslipidemia
sis by immunization with an anti-glycosaminoglycan mono-
clonal antibody in apolipoprotein E-deficient mice. Free Radic 
Biol Med. 2015;89:557-66. PMID: 26454078.
18 Qian W, Hasegawa J, Tsuno S, Endo Y, Matsuda A, Miura N. 
Effects of kampo formulas on the progression of hypercho-
lesterolemia and Fatty liver induced by high-cholesterol diet 
in rats. Yonago Acta Med. 2014;57:147-58.PMID: 25901102; 
PMCID: PMC4404525.
19 Shimada T, Akase T, Kosugi M, Aburada M. Preventive Ef-
fect of Boiogito on Metabolic Disorders in the TSOD Mouse, 
a Model of Spontaneous Obese Type II Diabetes Mellitus. 
Evid Based Complement Alternat Med. 2011;2011:931073. 
PMID: 19208721; PMCID: PMC3139392.
20 Liu ZL, Xie LZ, Zhu J, Li GQ, Grant SJ, Liu JP. Herbal medi-
cines for fatty liver diseases. Cochrane Database Syst Rev. 
2013;8:CD009059. PMID: 23975682.
21 Cheng Y, Tang K, Wu S, Liu L, Qiang C, Lin X, et al. As-
tragalus polysaccharides lowers plasma cholesterol through 
mechanisms distinct from statins. PloS one. 2011;6:e27437. 
PMID: 22110652.
22 Matsuda A, Wang Z, Takahashi S, Tokuda T, Miura N, 
Hasegawa J. Upregulation of mRNA of retinoid binding pro-
tein and fatty acid binding protein by cholesterol enriched-
diet and effect of ginger on lipid metabolism. Life Sci. 
2009;84:903-7. PMID: 19379761.
23 Wang X, Hasegawa J, Waka Shinoda, Akiko Matsuda, Miura N. 
[Effects of Hesperidin on the Progression of Hypercholester-
olemia and Fatty Liver Induced by High-Cholesterol Diet in 
Rats]. Jpn J Clin Pharmacol Ther. 2011;42(Suppl):S297. Japa-
nese.
24 Koopman R, Schaart G, Hesselink MK. Optimisation of oil 
red O staining permits combination with immunofluorescence 
and automated quantification of lipids.Histochem Cell Biol. 
2001;116:63-8. PMID: 11479724.
25 Del Moral ML, Esteban FJ, Torres MI, Camacho MV, 
Hernandez R, Jimenez A, et al. High-fat sunflower and olive 
oil diets affect serum lipid levels in steatotic rat liver differ-
ently. J Nutr Sci Vitaminol (Tokyo). 1997;43:155-60. PMID: 
9151249.
26 Rader DJ. High-density lipoproteins and atherosclerosis. Am J 
Cardiol. 2002;90:62i-70i. PMID: 12419482.
27 Keller H, Dreyer C, Medin J, Mahfoudi A, Ozato K, Wahli W. 
Fatty acids and retinoids control lipid metabolism through 
activation of peroxisome proliferator-activated receptor-
retinoid X receptor heterodimers. Proc Natl Acad Sci U S A. 
1993;90:2160-4. PMID: 8384714; PMCID: PMC46045.
28 Rosell M, Hondares E, Iwamoto S, Gonzalez FJ, Wabitsch M, 
Staels B, et al. Peroxisome proliferator-activated receptors-
alpha and -gamma, and cAMP-mediated pathways, control 
retinol-binding protein-4 gene expression in brown adipose 
tissue.Endocrinology. 2012;153:1162-73. PMID: 22253419.
29 Carta G, Murru E, Cordeddu L, Ortiz B, Giordano E, Belury MA, 
et al. Metabolic interactions between vitamin A and conjugat-
ed linoleic acid. Nutrients. 2014;6:1262-72. PMID: 24667133; 
PMCID: PMC3967192.
30 Shin MJ, Kang SM, Jang Y, Lee JH, Oh J, Chung JH, et al. 
Serum retinol binding protein 4 levels are associated with 
serum adiponectin levels in non-diabetic, non-obese subjects 
with hypercholesterolemia. Clin Chim Acta. 2007;378:227-9. 
PMID: 17250818.
31 Graham TE, Yang Q, Bluher M, Hammarstedt A, Ciaraldi TP, 
Henry RR, et al. Retinol-binding protein 4 and insulin re-
sistance in lean, obese, and diabetic subjects. N Engl J Med. 
2006;354:2552-63. PMID: 16775236.
32 Offner GD, Brecher P, Sawlivich WB, Costello CE, Troxler RF. 
Characterization and amino acid sequence of a fatty acid-
binding protein from human heart. Biochem J. 1988;252:191-
8. PMID: 3421901; PMCID: PMC1149123.
33 Glatz JF, van Bilsen M, Paulussen RJ, Veerkamp JH, 
van der Vusse GJ, Reneman RS. Release of fatty acid-binding 
protein from isolated rat heart subjected to ischemia and re-
perfusion or to the calcium paradox. Biochim Biophys Acta. 
1988;961:148-52. PMID: 3260112.
34 Zschiesche W, Kleine AH, Spitzer E, Veerkamp JH, Glatz JF. 
Histochemical localization of heart-type fatty-acid binding 
protein in human and murine tissues. Histochem Cell Biol. 
1995;103:147-56. PMID: 7634154.
35 Maatman RG, van de Westerlo EM, van Kuppevelt TH, 
Veerkamp JH. Molecular identification of the liver- and the 
heart-type fatty acid-binding proteins in human and rat kid-
ney. Use of the reverse transcriptase polymerase chain reac-
tion. Biochem J. 1992;288 (Pt 1):285-90. PMID: 1280113; 
PMCID: PMC1132111.
36 Cakir E, Ozbek M, Sahin M, Cakal E, Gungunes A, Ginis Z, 
et al. Heart type fatty acid binding protein response and sub-
sequent development of atherosclerosis in insulin resistant 
polycystic ovary syndrome patients. J Ovarian Res. 2012;5:45. 
PMID: 23249450; PMCID: PMC3574048.
37 Jing C, Beesley C, Foster CS, Chen H, Rudland PS, West DC, 
et al. Human cutaneous fatty acid-binding protein induces me-
tastasis by up-regulating the expression of vascular endothelial 
growth factor gene in rat Rama 37 model cells. Cancer Res. 
2001;61:4357-64. PMID: 11389060.
38 Layne MD, Patel A, Chen YH, Rebel VI, Carvajal IM, 
Pellacani A, et al. Role of macrophage-expressed adipocyte 
fatty acid binding protein in the development of accelerated 
atherosclerosis in hypercholesterolemic mice. FASEB J. 
2001;15:2733-5. PMID: 11606480.
39 Kushiro M, Takahashi Y, Ide T. Modulation of cutaneous 
fatty acid-binding protein mRNA expression in rat adipose 
tissues by hereditary obesity and dietary fats. J Oleo Sci. 
2007;56:533-41. PMID: 17898460.
40 Davies JP, Levy B, Ioannou YA. Evidence for a Niemann-pick 
C (NPC) gene family: identification and characterization of 
NPC1L1. Genomics. 2000;65:137-45. PMID: 10783261.
41 Graf GA, Yu L, Li WP, Gerard R, Tuma PL, Cohen JC, et al. 
ABCG5 and ABCG8 are obligate heterodimers for protein 
trafficking and biliary cholesterol excretion. J Biol Chem. 
2003;278:48275-82. PMID: 14504269.
42 Kuksis A, Marai L, Myher JJ, Geher K. Identification of plant 
sterols in plasma and red blood cells of man and experimental 
animals. Lipids. 1976;11:581-6. PMID: 972575.
43 Weihrauch JL, Gardner JM. Sterol content of foods of plant 
origin. J Am Diet Assoc. 1978;73:39-47. PMID: 659760.
44 Kempen HJ, Glatz JF, Gevers Leuven JA, van der Voort HA, 
Katan MB. Serum lathosterol concentration is an indicator 
of whole-body cholesterol synthesis in humans. J Lipid Res. 
1988;29:1149-55. PMID: 3183524.
45 Lees AM, Mok HY, Lees RS, McCluskey MA, Grundy SM. 
Plant sterols as cholesterol-lowering agents: clinical trials in 
patients with hypercholesterolemia and studies of sterol bal-
ance. Atherosclerosis. 1977;28:325-38. PMID: 597345.
46 Miettinen TA, Tilvis RS, Kesaniemi YA. Serum plant sterols 
and cholesterol precursors reflect cholesterol absorption and 
synthesis in volunteers of a randomly selected male popula-
tion. Am J Epidemiol. 1990;131:20-31. PMID: 2293749.
80
W. Qian et al.
47 Jones PJ. Cholesterol-lowering action of plant sterols. Current 
atherosclerosis reports. 1999;1:230-5. PMID: 11122715.
48 Silbernagel G, Fauler G, Renner W, Landl EM, Hoffmann MM, 
Winkelmann BR, et al. The relationships of cholesterol me-
tabolism and plasma plant sterols with the severity of coronary 
artery disease.J Lipid Res. 2009;50:334-41. PMID: 18769018.
49 Noto D, Cefalù AB, Barraco G, Martino E, Fayer F, Minà M, 
et al. Plasma non-cholesterol sterols: a useful diagnostic tool 
in pediatric hypercholesterolemia. Pediatr Res.2010;67:200-4. 
PMID: 20091938.
50 Brahma Naidu P, Uddandrao VV, Ravindar Naik R, Suresh P, 
Meriga B, Begum MS, et al. Ameliorative potential of gin-
gerol: Promising modulation of inflammatory factors and lipid 
marker enzymes expressions in HFD induced obesity in rats. 
Mol Cell Endocrinol. 2016;419:139-47. PMID: 26493465.
51 Yang X, Coriolan D, Murthy V, Schultz K, Golenbock DT, 
Beasley D. Proinflammatory phenotype of vascular smooth 
muscle cells: role of efficient Toll-like receptor 4 signaling. 
Am J Physiol Heart Circ Physiol. 2005;289:H1069-76. PMID: 
15863460.
52 Anand AR, Bradley R, Ganju RK. LPS-induced MCP-1 ex-
pression in human microvascular endothelial cells is mediated 
by the tyrosine kinase, Pyk2 via the p38 MAPK/NF-kappaB-
dependent pathway. Mol Immunol. 2009;46:962-8. PMID: 
18954908; PMCID: PMC2680789.
53 Panee J. Monocyte Chemoattractant Protein 1 (MCP-1) 
in obesity and diabetes. Cytokine. 2012;60:1-12. PMID: 
22766373; PMCID: PMC3437929.
54 Siebert H, Sachse A, Kuziel WA, Maeda N, Bruck W. The 
chemokine receptor CCR2 is involved in macrophage recruit-
ment to the injured peripheral nervous system. J Neuroimmu-
nol. 2000;110:177-85. PMID: 11024548.
55 Li Q, Sun W, Wang X, Zhang K, Xi W, Gao P. Skin-Derived 
Mesenchymal Stem Cells Alleviate Atherosclerosis via 
Modulating Macrophage Function. Stem Cells Transl Med. 
2015;4:1294-301. PMID: 26400926; PMCID: PMC4622403.
56 Nighoghossian N, Derex L, Douek P. The vulnerable carotid 
artery plaque: current imaging methods and new perspectives. 
Stroke. 2005;36:2764-72. PMID: 16282537.
57 Fotis L, Agrogiannis G, Vlachos IS, Pantopoulou A, Margoni A, 
Kostaki M, et al. Intercellular adhesion molecule (ICAM)-1 
and vascular cell adhesion molecule (VCAM)-1 at the early 
stages of atherosclerosis in a rat model. In vivo. 2012;26:243-
50. PMID: 22351665.
58 Yao EH, Wang HJ, Xu CS. Effects of tongxinluo on the neo-
intima formation and expression of inflammatory cytokines 
in rats after carotid artery balloon injury. Indian J Pharmacol. 
2014;46:510-4. PMID: 25298580; PMCID: PMC4175887.
59 Wang D, Zhuang Y, Tian Y, Thomas GN, Ying M, Tomlinson B. 
Study of the effects of total flavonoids of Astragalus on ath-
erosclerosis formation and potential mechanisms. Oxid Med 
Cell Longev. 2012;2012:282383. PMID: 22496932; PMCID: 
PMC3306992.
